Statement by Blue Earth Diagnostics on COVID-19 click here for more information

Latest News From Blue Earth Diagnostics


Blue Earth Diagnostics receives £18M Series B Funding from Syncona Partners and establishes Blue Earth Diagnostics Inc

Blue Earth Diagnostics Ltd (“BED”), a private diagnostics company, announces today that it has received…

Blue Earth Diagnostics granted US and European orphan drug designation for fluciclovine (18F) in the diagnosis of glioma

Blue Earth Diagnostics Ltd (“BED”), a private diagnostics company, announces today that it has received…

Blue Earth Diagnostics signs an agreement with Siemens’ PETNET Solutions to manufacture and distribute prostate cancer PET imaging agent

Blue Earth Diagnostics Ltd (“BED”), a private diagnostics company, has entered into an exclusive agreement…

Syncona announces the formation of Blue Earth Diagnostics, a company developing PET agents for the detection of recurrent prostate cancer

Syncona Partners LLP (“Syncona”) announces a £12.8 million investment in Blue Earth Diagnostics Ltd (“BED”),…